R-Biopharm Group Receives FDA Clearance for RIDASCREEN® Norovirus 3rd Generation EIA Antigen Detecti

R-Biopharm Group Receives FDA Clearance for RIDASCREEN® Norovirus 3rd Generation EIA Antigen Detection Assay FDA permits marketing of first test for most common cause of gastroenteritis outbreaks. The test can aid in identifying and containing norovirus outbreaks. Washington, MO (PRWEB) February 24, 2011 R-Biopharm Group, Washington, MO, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its antigen detection assay, RIDASCREEN® Norovirus 3rd Generation EIA, as an aid in investigating the possible cause for acute gastroenteritis
Contributor
PR Web
PR Web
Lanham, Maryland
Law Marketing
1.800.345.5572
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Download

Related Documents in PR Web
MCLE Sales

Categories